Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1675
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19345133 | LEUPROLIDE ACETATE COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT BREAST CANCER | Non-Final OA | Tolmar International Limited |
| 17638428 | GENE FRAGMENT OVEREXPRESSION SCREENING METHODOLOGIES, AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 17639014 | STAPLED BETA-CATENIN LIGANDS | Non-Final OA | Ohio State Innovation Foundation |
| 17638600 | HEMOGLOBIN-BASED NANOPARTICLES FOR OXYGEN DELIVERY | Final Rejection | Ohio State Innovation Foundation |
| 18643038 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Non-Final OA | Novo Nordisk A/S |
| 17785518 | TERLIPRESSIN-OCTADECANEDIOIC ACID CONJUGATE FOR VASOCONSTRICTIVE THERAPY | Non-Final OA | Northwestern University |
| 18020908 | N-ACYL AMINO ACID PRODUCTS AND USES | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18359728 | PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES | Non-Final OA | Allergan Pharmaceuticals International Limited |
| 17794338 | MODULATING LYMPHATIC VESSELS IN NEUROLOGICAL DISEASE | Non-Final OA | University of Virginia Patent Foundation |
| 18203348 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | Final Rejection | Sutro Biopharma, Inc. |
| 18316496 | CONJUGATES OF MONTELUKAST AND PEPTIDES | Final Rejection | ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD |
| 18591891 | COMPOSITIONS AND METHODS FOR INHIBITING HAIR GROWTH | Non-Final OA | Elise A. Olsen |
| 17766137 | COMPOSITION COMPRISING GLUCAGON AND GLP-1 AND GIP RECEPTOR DUAL AGONIST AND THERAPEUTIC USE OF SAME | Final Rejection | HANMI PHARM. CO., LTD. |
| 18519014 | FUSION PEPTIDES OR PROTEINS, THEIR USE, AND SYSTEMS AND KITS BASED THEREUPON, FOR THE SEPARATION AND/OR DETECTION OF PLASTICS, PARTICULARLY OF MICROPLASTICS | Final Rejection | DWI-Leibniz-Institut Fur Interaktive Materialien E.V. |
| 17908524 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | PHARMA MAR, S.A. |
| 18471413 | COMPOSITIONS OF EXENDIN-4 DERIVATIVES | Final Rejection | AMYLYX PHARMACEUTICALS, INC |
| 16973782 | PEPTIDIC PROTEIN KINASE C INHIBITORS AND USES THEREOF | Final Rejection | UNIVERSITE DE GENEVE |
| 16763409 | COMPOSITION AND METHOD OF TREATMENT FOR DRY A.M.D. (AGE RELATED MACULAR DEGENERATION) | Non-Final OA | EYE CO PTY LTD |
| 18249648 | ACCELERATING TOOTH REMINERALISATION AND BONE REGENERATION WITH SELF-ASSEMBLING PEPTIDES AND AMORPHOUS CALCIUM PHOSHATE | Non-Final OA | CREDENTIS AG |
| 17791395 | ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING TAU EXPRESSION | Non-Final OA | Sangamo Therapeutics, Inc. |
| 18246699 | Application of Lactoferrin in Prevention and Treatment of Alzheimer's Disease | Non-Final OA | Hainan Xingzheng Nutrition Engineering Co., Ltd |
| 18184427 | COMPLEMENTOME ASSAY | Non-Final OA | Complement Therapeutics Limited |
| 17595390 | HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE | Non-Final OA | CSL BEHRING AG |
| 17875117 | STABLE PEPTIDE FORMULATIONS FOR ORAL USE | Final Rejection | Aurobindo Pharma Ltd |
| 18000358 | DIAGNOSIS, PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | EMERGEX VACCINES HOLDING LIMITED |
| 17924651 | PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE | Non-Final OA | PHARMATHEN S.A. |
| 17922269 | TREATMENT AND/OR PREVENTION OF A DISEASE OR A SYNDROME RELATED TO A VIRUS INFECTION | Final Rejection | Ageronix SA |
| 17918932 | USING C1 ESTERASE INHIBITOR TO TREAT VIRAL INFECTION-RELATED ACUTE RESPIRATORY DISTRESS | Non-Final OA | Pharming Intellectual Property B.V. |
| 17909730 | CYCLIC PEPTIDES FROM THE C-TERMINUS OF ACETYLCHOLINESTERASE FOR TREATMENT OF SKIN DISORDERS AND FOR COSMETICAL USE | Non-Final OA | NEURO-BIO LTD |
| 17790936 | WOUND DRESSINGS WITH ACID-INDUCED GROWTH FACTOR RELEASE | Final Rejection | Systagenix Wound Management, Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy